Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 % of patients. Since IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by...

Descripción completa

Detalles Bibliográficos
Autores principales: Panelli, Monica C, White, Richard, Foster, Mareva, Martin, Brian, Wang, Ena, Smith, Kina, Marincola, Francesco M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC434535/
https://www.ncbi.nlm.nih.gov/pubmed/15175100
http://dx.doi.org/10.1186/1479-5876-2-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC434535/
https://www.ncbi.nlm.nih.gov/pubmed/15175100
http://dx.doi.org/10.1186/1479-5876-2-17

Ejemplares similares